Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities

Treatment of metastatic renal cell carcinoma (mRCC) has evolved rapidly over the last two decades as major pathways involved in pathogenesis have been elucidated. These include the vascular endothelial growth factor (VEGF) axis and mammalian target of rapamycin (mTOR). Therapies targeting the VEGF p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Roger B., Oudard, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432793/
https://www.ncbi.nlm.nih.gov/pubmed/22327313
http://dx.doi.org/10.1007/s10637-012-9796-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432793/
https://www.ncbi.nlm.nih.gov/pubmed/22327313
http://dx.doi.org/10.1007/s10637-012-9796-8

Ejemplares similares